TSPO and glioblastoma: Angiopoietin-2 (Ang-2), an angiogenic growth factor, was overexpressed in bevacizumab-treated glioblastomas, while translocator protein (TSPO) was upregulated in bevacizumab-treated glioblastomas and promoted apoptosis resistance.